Mosaic Mitral Valve: Long-Term Outcomes in Patients Under 65

Recruiting now

Conditions studied: Valve Disease, Heart, Valve Replacement, Valve Regurgitation, Mitral, Valve Heart Stenosis

In brief

The safety and efficacy of the Mosaic bioprosthetic heart valves for cardiac valve replacement in the aortic position has been well documented throughout the literature. However, few studies assessing structural valve deficiency, patient outcomes and overall product performance in patients under the age of 65 exists for the Mosaic mitral valve bioprosthetic. This study aims to assess valve efficacy, stability, and post operative outcomes in patients who have received the Mosaic mitral valve prothesis at ProMedica Toledo Hospital and were under the age of 65.

Key facts

Study ID

NCT06917586

Run by

Michael Moront

People needed

300

Starts

2025-01-01

Expected to finish

2027-07-01

Last updated by the study team

2026-02-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Received the Mosaic Mitral Valve Bioprosthetic at ProMedica Toledo Hospital
• Under the age of 65

You may not qualify if…

• Over the age of 65
• Under the age of 18
• Surgery performed at institutions outside of ProMedica Toledo Hospital

Where it is running

• ProMedica Toledo Hospital — Toledo, Ohio, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.